Is alteplase safe and effective in routine clinical practice for patients with ischemic stroke?

摘要

Recombinant tissue plasminogen activator (rtPA; alteplase) is the only thrombolytic agent licensed for the treatment of patients with acute ischemic stroke. One of the conditions of licensing in the European Union was the initiation of the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) to examine the safety of this treatment in routine clinical practice.